



Chiral LC/MS Analysis of Methamphetamine in Urine on Astec® CHIROBIOTIC® V2

Differentiation of Illicit D-Methamphetamine from Over-the-Counter L-Methamphetamine by LC-MS

Contributed Article

The following was generated with the assistance of an outside source using Sigma-Aldrich® products. Technical content was generated and provided by:

Marc D. Julliard¹, Jason E. Strull¹, Dylan M. Stone¹ and David S. Bell²


¹ MD Labs Pain Management Toxicology, Reno, Nevada, U.S.A.

² Sigma-Aldrich/Supelco, Bellefonte, PA, U.S.A.



Methamphetamine (**Figure 1**) is a powerful stimulant, often used as a recreational drug of abuse or as a doping agent in sports. Its presence in urine is screened for by enzymatic immunoassays and confirmed using a hyphenated mass spectrometry chromatographic method. However, this molecule exists in two enantiomeric forms, L-methamphetamine (or levo-methamphetamine), a vasoconstrictor used in the formulation of over-the-counter medications such as Vicks® Vapor Inhaler and D-Methamphetamine, the illicit stimulant.¹ Immunoassay does not differentiate between the legal and illicit versions and therefore will report a positive finding if either are detected in the specimen above cutoff concentrations. The same holds true for reverse-phase LC-MS techniques that are commonly used in toxicology for drug of abuse quantitation.

Figure 1. Structure of D- and L-Methamphetamine



This poses a problem when analyzing specimens from patients who are using the legal decongestants or medications such as selegiline and fenproporex, which may metabolize to methamphetamine². To confirm which molecule is present in a specimen testing positive by immunoassay for methamphetamine, a chiral LC-MS method was developed using an Astec CHIROBIOTIC V2 HPLC column. The method was applied to real patient samples allowing such differentiation with an extremely high level of accuracy.

Experimental

Standard (rac)-methamphetamine and (L)-methamphetamine were purchased from Cerilliant, TX, U.S.A. Urine samples were obtained from patients visiting pain management clinics and as part of a random drug-testing program aimed at monitoring for prescription compliance. All specimens were stored at -4 °C and thawed on the morning prior to analysis. For analysis by chiral LC-MS/MS, samples were processed as follows: To a 125 µL aliquot was added 1 mL of diethyl ether. The diluted sample was vortexed for 30 minutes and centrifuged at 10,000 rpm for 10 minutes. A 500 µL aliquot of the organic supernatant was evaporated to dryness at 56 °C in a heating block. The dried extracts were resuspended in 0.5 mL of starting mobile phase and 10 µL were injected onto the column. Analysis of patient samples was preceded by the injection of an authentic spiked standard sample containing both enantiomers in methanol (D:L, 1:3).

The liquid chromatography system (Waters® AQUITY UPLC®, Waters, Milford MA, U.S.A.) was run in isocratic mode, without temperature control using an Astec CHIROBIOTIC V2 column (25 cm x 4.6 mm, 5 µm) from Sigma-Aldrich/Supelco, Bellefonte, PA, U.S.A. The mobile phase consisted of 0.04% w/v ammonium trifluoroacetic acid in water:methanol (5:95, v/v) and the flow rate was set at 1 mL/min.* Total run time was 13.00 minutes. Retention times were 10.75 and 11.62 min for D- and L-methamphetamine, respectively. The mass spectrometer (MS, Waters) was operated in ESI+ and MRM modes. The two following transitions were monitored for positive identification of both enantiomeric compounds, 150.0→91.0 and 150.0→119.0. Peak smoothing and integration were carried out to determine relative ratios using the MassLynx™ software. D- and L- peak assignments were established by comparison of retention times with the spiked standard sample.


Results

Chiral separation of D- and L-methamphetamine using the Astec CHIROBIOTIC V2 column and the methanol-ammonium trifluoroacetic acid mobile phase was successfully applied to the analysis of real patient urine samples that had previously been identified as positive for methamphetamine by quantitative analysis on a C18 column. **Figure 2** provides chromatographic traces of standards as well as several patient samples. **Trace 1** in the figure shows a 1:3 standard mixture of D- and L-methamphetamine, respectively. **Traces 2** through **4** show the response of D-methamphetamine in patient samples, indicating illicit use of the drug by these patients. The L-methamphetamine response in **Trace 5** indicates legal use of OTC-derived L-methamphetamine.


Figure 2. Chiral LC-MS/MS Separation of D- and L-Methamphetamine Enantiomers on Astec CHIROBIOTIC V2

sample/matrix: Urine extracted as described in experimental section. Final concentration of spiked standards in Trace 1 represents 500 ng/mL (D-methamphetamine) and 1,500 ng/mL (L-methamphetamine) in urine
 column: Astec CHIROBIOTIC V2, 25 cm x 4.6 mm, 5 µm particles (11024AST)
 mobile phase: 0.04% ammonium trifluoroacetic acid in water:methanol (5:95, v/v)
 flow rate: 0.45 mL/min
 column temp: ambient (20-22 °C)
 detector: MS, ESI(+), MRM, 150.0/91.0, 150.0/110.0
 injection: 250 µL


Trace 1: 1:3, D:L-Methamphetamine Standard




Trace 2: Patient Sample – ILLICIT, D-Methamphetamine Positive




Trace 3: Patient Sample – ILLICIT, D-Methamphetamine Positive



Trace 4: Patient Sample – ILLICIT, D-Methamphetamine Positive



Trace 5: Patient Sample – LEGAL, L-Methamphetamine Positive



Conclusion

Screening studies for illicit drugs require confirmation. In the case of methamphetamine, the positive results from screening studies are often the result of metabolism of prescribed therapeutics or the inability of the method to differentiate between D-methamphetamine and the enantiomer, L-methamphetamine, found in OTC medications. Astec CHIROBIOTIC V2 is shown to efficiently separate methamphetamine enantiomers using LC/MS-compatible conditions allowing sensitive differentiation of stereoisomer forms present in urine.

References

- Esposito, F. M.; Crumpton, S.; Mitchell, J.; Flegel, R. R. Evaluation of the 20% D-methamphetamine requirement for determining illicit use of methamphetamine in urine. *J. Anal. Toxicol.* 36(6), 2012, 399-404.
- Kraemer, T.; Maurer, H. H. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. *Journal of Chromatography B: Biomedical Sciences and Applications.* 713(1), 1998, 163-187.

+ Featured Products

Description	Cat. No.
Astec CHIROBIOTIC V2, 25 cm x 4.6 mm, 5 µm	11024AST
(±)-Methamphetamine (Cerilliant® Certified Reference Material)	M-022
R(-)-Methamphetamine (levo-Methamphetamine) (Cerilliant® Certified Reference Material)	M-024
S(+)-Methamphetamine (dextro-Methamphetamine) (Cerilliant® Certified Reference Material)	M-020

*Mobile phase is prepared by dissolving 0.4 g ammonium trifluoroacetate into a solution of 950 mL methanol and 50 mL water and mixing well.

Enabling Science to
Improve the Quality of Life

Order/Customer Service (800) 325-3010 • Fax (800) 325-5052
 Technical Service (800) 325-5832 • sigma-aldrich.com/techservice
 Development/Custom Manufacturing Inquiries **SAFC**® (800) 244-1173
 Safety-related Information sigma-aldrich.com/safetycenter

World Headquarters
 3050 Spruce St.
 St. Louis, MO 63103
 (314) 771-5765
sigma-aldrich.com